News Conference News ESC 2024 Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events Michael O'Riordan September 01, 2024
News Conference News ESC 2024 Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events Caitlin E. Cox August 31, 2024
News Conference News ESC 2022 Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE Michael O'Riordan August 31, 2022
News Conference News ESC 2022 Polypill Bests Usual Care in Patients With Recent MI: SECURE Michael O'Riordan August 26, 2022
News Conference News ESC 2021 Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention Michael O'Riordan August 31, 2021
News Conference News ESC 2016 Optimal Approach for BP Lowering Debated Amid New J-Curve Signals in Stable CAD Todd Neale September 09, 2016
News Conference News ESC 2016 When Unblinded to Statin Therapy, Patients’ Muscle-Related Adverse Events Shoot Up: ASCOT Analysis Michael O'Riordan August 31, 2016
News Conference News ESC 2016 Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER Michael O'Riordan August 30, 2016
News Conference News ESC 2015 Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes Yael L. Maxwell September 01, 2015
News Conference News ASCOT: Unexplained Long-Term Mortality Benefit Found with Atorvastatin August 29, 2011